Inhaled Budesonide as a treatment for COVID-19

A recently published study showed the effectiveness of inhaled Budesonide in the treatment of COVID-19. Specifically, inhaled budesonide reduced the severity of the disease and shortned the time to recovery. Having worked with inhaled Budesonide (suspension) for several years, I really think this is an encouraging result. Senior author Mona Bafadhel is a reknowned scientist in this area. See more details here...

New inhaled therapies for viral infections

One of our customers, Activoris Medizintechnik GmbH, today announced the strategic collaboration with CytoTools AG (ISIN DE000A0KFRJ1) for the development of respiratory treatments against diseases like COVID-19 and Influenza. ACliRA Consulting GmbH will be supporting this development with its expertise in scientific and regulatory strategy advice. See more details here...

Free rapid scientific advice for COVID-19 treatments or vaccines

EMA has put in place a rapid scientific advice procedure for potential COVID-19 treatments and vaccines, which is free of charge.

The rapid procedure reduces review time to a maximum of 20 days (from 40-70 days), with no pre-specified submission deadlines.

In addition, flexibility can be agreed on a case-by-case basis on the type and extent of the briefing dossier.

For more information, see:

EMA and the COVID-19 EMA pandemic Task Force can provide early guidance to developers whose development plan is not yet suitable for formal rapid scientific advice.

Contact us if you need assistance in preparing such a submission. We will make sure that the documents are diligently prepared so that you can get the most out of such a scientific advice procedure.

QrumPharma acquired by MannKind Corp.

One of our longstanding clients, QrumPharma LLC based in Doylestown, PA, USA, has been acquired by MannKind Corporation just recently.

See full details in the press release here: https://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-expands-its-pipeline-acquisition-qrumpharma-inc

We are delighted that this project has come to such a huge success and thank the team at QrumPharma for the longstanding and very amicable cooperation. We wish all of you, but also of course the project for developing inhaled Clofazimine for the treatment of NTM, utmost success in the future!

Many approved drugs potentially beneficial for Covid-19

Nearly a dozen approved drugs could be effective against Covid-19, a study published in Nature says.

Find more details here:

https://www.nature.com/articles/s41586-020-2286-9

https://www.medscape.com/viewarticle/929739?src=wnl_edit_tpal&uac=166664ER&impID=2367783&faf=1

Click here to contact us!

Successful clinical development. Period.
+49-6424-7109977
Hohmannsweg 8, 35085 Ebsdorfergrund, Germany